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Abstract
The type III interferon (IFN) receptor is preferentially expressed by epithelial cells. It is made of two subunits: IFNLR1, which
is specific to IFN-lambda (IFN-l) and IL10RB, which is shared by other cytokine receptors. Human hepatocytes express
IFNLR1 and respond to IFN-l. In contrast, the IFN-l response of the mouse liver is very weak and IFNLR1 expression is hardly
detectable in this organ. Here we investigated the IFN-l response at the cellular level in the mouse liver and we tested
whether human and mouse hepatocytes truly differ in responsiveness to IFN-l. When monitoring expression of the IFN-
responsive Mx genes by immunohistofluorescence, we observed that the IFN-l response in mouse livers was restricted to
cholangiocytes, which form the bile ducts, and that mouse hepatocytes were indeed not responsive to IFN-l. The lack of
mouse hepatocyte response to IFN-l was observed in different experimental settings, including the infection with a
hepatotropic strain of influenza A virus which triggered a strong local production of IFN-l. With the help of chimeric mice
containing transplanted human hepatocytes, we show that hepatocytes of human origin readily responded to IFN-l in a
murine environment. Thus, our data suggest that human but not mouse hepatocytes are responsive to IFN-l in vivo. The
non-responsiveness is an intrinsic property of mouse hepatocytes and is not due to the mouse liver micro-environment.
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Introduction
The type III interferon (IFN) family was discovered about 10
years ago by two independent groups [1,2]. Three type III IFN
subtypes have been described, IFN-l1, IFN-l2 and IFN-l3, also
named IL29, IL28A and IL28B, respectively [1,2]. A fourth IFN-
l-coding sequence was found in some allelic variants [3]. In mice,
only IFN-l2 and IFN-l3 are expressed since IFN-l1 is a
pseudogene [1,2,4]. Type III IFNs signal through a heterodimeric
receptor composed of the IFN-l-specific IFNLR1 chain and the
IL10RB chain which is shared by other IL-10 cytokine family
members [1,2,5]. Although type I and type III IFNs use distinct
receptors, they both signal via the Jak-STAT pathway, leading to
phosphorylation of STAT1 and STAT2 and to formation of the
ISGF3 complex by association with IRF9. Consequently, type I
and type III IFNs upregulate the same group of IFN-stimulated
genes (ISGs), which code for proteins such as Mx or OAS that
mediate antiviral activity [4–7]. However, type I and type III IFNs
differ with regard to their receptor distribution. While the type I
IFN receptor (IFNAR) is reportedly expressed by all nucleated
cells, the IFNLR1 chain of the type III IFN receptor is
preferentially expressed by epithelial cells [8]. Consequently,
IFN-l is expected to be a good alternative to type I IFNs for the
treatment of some viral diseases, as fewer side effects are expected
due to the more restricted range of IFN-l target cells. Accordingly,
IFN-l entered phase III clinical trials as a candidate drug against
hepatitis C virus (HCV) infection.
Due to their epithelial nature, hepatocytes are expected to
respond to IFN-l. Studies with human primary hepatocytes
convincingly showed that these cells express the IFN-l receptor
complex and respond to IFN-l [9–11]. Further, IFNLR1 was
shown to be expressed in primary human hepatocytes and in some
human hepatoma cell lines. Accordingly, Mx and OAS were
induced after treatment of primary human hepatocytes with
pegylated IFN-l1 [11]. More recently, Dickensheets et al.
confirmed responsiveness of primary human hepatocytes, although
the magnitude of ISG expression in response to IFN-l was lower
than that induced by an equivalent concentration of IFN-a [9].
Muir et al. observed an antiviral activity of IFN-l against HCV in
chronically infected patients [12]. In contrast, in the mouse, the
IFN-l response is very weak in the liver and IFNLR1 expression is
hardly detected in this organ [8,13]. Accordingly, IFN-l was
ineffective against hepatotropic viruses such as Thogoto virus and
Rift valley virus [13]. Further, in mice expressing the firefly
luciferase gene under transcriptional control of the IFN-inducible
Mx2 promoter, injection of IFN-l did not induce a detectable
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response in the liver [14]. Consistent with these data, Pagliacetti
and colleagues found that IFN-l2 only weakly inhibited HBV
replication when injected intravenously in HBV-transgenic mice,
as compared to the inhibition observed with IFN-b or IFN-c [15].
As a first approach to more thoroughly investigate the IFN-l
response in the mouse liver, we used mice carrying a functional
Mx1 gene [16] that permit measuring IFN responses with high
sensitivity at the single cell level [8,17]. Using this system, we
found that although mouse hepatocytes can respond to IFN-a,
they do not respond to IFN-l. Instead, we observed a strong IFN-
l response in cholangiocytes, the epithelial cells forming the bile
ducts. Finally, using chimeric mice that were transplanted with
human hepatocytes [18], we demonstrated that human but not
mouse hepatocytes are responsive to IFN-l under identical
experimental conditions in vivo.
Materials and Methods
Animal Experiments
Ethics statement: Handling of mice (agreement LA1230472)
and experimental procedures were conducted in accordance with
the EEC directive 86/609/CEE and the related Belgian law of
April 6th 2010. The study and protocol used in this study were
approved by the ethics committee of the University of Louvain
under the agreement # 2010/UCL/MD/031.
Six to 9 week-old C57BL/6 mice carrying a functional Mx1
gene (B6.A2G-Mx1, designated Mx-wt) were from the breeding
colony at the University of Freiburg, Germany. B6.A2G-Mx1 mice
either lacking a functional type I IFN receptor (designated Mx-
IFNAR10/0), a functional type III IFN receptor (designated Mx-
IFNLR10/0) or both (designated Mx-IFNAR10/0 IFNLR10/0)
were described previously [13]. 12 to 13 week-old chimeric human
liver-uPA-SCID mice were generated in the animal facility of the
Faculty of Medicine and Health Sciences at the Ghent University.
Briefly, 2-week old transgenic SCID mice overexpressing the
urokinase-type plasminogen activator (uPA) gene under the
control of the albumin promoter were xenografted with about 1
million primary human hepatocytes (donor HH223; BD Biosci-
ences, Erembodegen, Belgium) as previously described [18].
Engraftment and repopulation of the mouse liver by the
transplanted human hepatocytes was evaluated by quantifying
the amount of human albumin present in the mouse plasma
(Bethyl Laboratories, Montgomery, Tx).
Plasmids
All plasmids used in this work are pcDNA3 (Invitrogen)
derivatives. The primer sequences used in this work are presented
in table 1. The plasmids pcDNA3-muIFNaA, pcDNA3-muIF-
Na6T and pcDNA3-muIFNl3 were described previously [8,19].
HuIFN-l3 was cloned from TOPO-huIFNl3 (Source Bioscience)
into pcDNA3 (Invitrogen). The PCR-amplified fragment was
cloned into pcDNA3 using the HindIII and Asp718 restriction
sites. HuIFN-a2 was amplified from HeLa cells DNA, The PCR-
amplified fragment was cloned into pcDNA3 using EcoRI and NotI
restriction sites.
Virus Infection
TURH (H7/N1) virus is a mouse-adapted hepatotropic variant
of influenza virus strain A/TURKEY/England 63 (Havl, Nav3)
[20]. 8–9 week-old Mx-IFNAR10/0 and Mx-IFNLR10/0 mice
were used in this experiment. For each genotype, twelve mice were
infected intraperitoneally with 104 plaque-forming units (pfu) of
TURH. Livers were collected at 24 h (n = 2) and 48 h (n = 6) post
infection. Four mice, used as negative control, received phosphate
buffer saline (PBS) and were sacrificed after 48 h.
DNA Electroinjection and Recombinant IFN
Administration
Mx-wt mice or chimeric human liver uPA-SCID mice were
anesthetized and electroinjected as previously described [8].
Briefly, 10 mg of endotoxin-free plasmid DNA (Quiagen endofree)
suspended in PBS, were injected in a volume of 25 ml in the left
and right tibialis anterior muscles. DNA was electroporated using
Table 1. Primers.
Gene amplified Primer sequencec,d
huIFN-l3 (f) 59-AAA AAA GCT TAC CAT GAC CGG GGA CTG CAT GCC-39
(r) 59-AAA AGG TAC CTC AGA CAC ACA GGT CCC CGC T-39
huIFN-a2 (f) 59-AAA AGA ATT CAC CAT GGC CTT GAC CTT TGC TTT-39
(r) 59-AAA AGC GGC CGC TCA TTC CTT ACT TCT TAA ACT TT-39
influenza A (f) 59-AAG ACC AAT CCT GTC ACC TCT GA-39
(r) 59-CAA AGC GTC TAC GCT GCA GTC C-39
mOASl2 (f) 59-GGA TGC CTG GGA GAG AAT CG-39
(r) 59-TCG CCT GCT CTT CGA AAC TG-39
hOAS1a (f) 59-AGA AAG AGG GCG AGT TCT CC-39
(r) 59-TGG GCT GTG TTG AAA TGT GT-39
hMxAb (f) 59-TTC AGC ACC TGA TGG CCT ATC-39
(r) 59-CCG TAC GTC TGG AGC ATG AAG-39
b-actin (f) 59- AGA GGG AAA TCG TGC GTG AC-39
(r) 59- CAA TAG TGA TGA CCT GGC CGT-39
aSequence kindly provided by Professor Stephan Brand, University Hospital Munich-Grosshadern, University of Munich, Germany.
b[32].
c(f) forward primer; (r) reverse primer.
dFor RT-qPCR, annealing reactions were performed at 63uC for influenza A virus and at 60uC for mOASl2, hOAS1, hMxA and b-actin.
doi:10.1371/journal.pone.0087906.t001
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a Cliniporator system (Cliniporator, IGEA, Carpi, Italy). Mice
were then woken up by intraperitoneal injection of 250 ml of
Atipamezol 500 mg/ml (Antisedan) and kept in an insulator for
7 days prior to sacrifice and organ harvest. For recombinant IFN
administration, 6–8 week-old Mx-IFNAR10/0, Mx-IFNLR10/0 or
Mx-IFNAR10/0 IFNLR10/0 were treated subcutanously with
100 ml of PBS containing either 1 mg of cross-reactive human
Figure 1. Cholangiocytes are the main IFN-l-responsive cells in mouse livers. A: Fluorescence microscopy images showing co-
immunostainings of Mx1 (green) and cytokeratin (red) in liver sections from Mx-IFNAR10/0 mice electroinjected with IFN-l expression plasmid. B:
Fluorescence microscopy images showing co-immunostainings of Mx1 (green) and cytokeratin (red) in liver sections from Mx-IFNLR10/0 mice
electroinjected with IFN-a expression plasmid. Arrowheads point to intersticial cells; arrow points to endothelial cell. C: Immunofluorescent detection
of Mx1 (red) in liver sections of mice that received a single subcutaneous dose of IFN. Left panel: Mx-IFNLR10/0 mice inoculated with IFN-a; central
panel: Mx-IFNAR10/0 mice inoculated with IFN-l; right panel: control Mx-IFNAR10/0 IFNLR10/0 inoculated with IFN-a and IFN-l. Nuclei were stained
with DAPI. Arrows point to Mx1-positive hepatocytes identified by their large nuclei.
doi:10.1371/journal.pone.0087906.g001
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Figure 2. IFN response in mice infected with the TURH influenza A virus strain. A: Immunofluorescence detection of TURH influenza A virus
in liver sections from Mx-IFNAR10/0 and Mx-IFNLR10/0 mice infected for 48 hours or mock-infected, using anti-influenza A virus antibody (Red) and
Hoechst staining of nuclei (blue). Results are representative of two independent experiments. B–C: RT-qPCR analysis of influenza A virus replication in
the liver (B) and lungs (C) of Mx-IFNAR10/0 and Mx-IFNLR10/0 mice. Results are expressed as influenza A virus cDNA copies per 105 copies of b-actin
cDNA. D–E: RT-qPCR analysis of Oasl2 expression in the liver (D) and lungs (E) of Mx-IFNAR10/0 and Mx-IFNLR10/0 infected mice. Results are expressed
as mOasl2 cDNA copies per 103 copies of b-actin cDNA. F–G: IFN-b (F) and IFN-l (G) production in the liver of infected mice. Results are expressed as
IFN cDNA copies per 105 copies of b-actin cDNA. It is noteworthy that cells from IFNAR10/0 expressed lower basal levels of IFN, likely as a consequence
of a disrupted positive feed-back loop for IFN expression in these mice.
doi:10.1371/journal.pone.0087906.g002
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IFN-aB/D [21], 1 mg of recombinant mouse IFN-l2 (PeproTech),
or a mixture of both cytokines.
RNA Extraction and Quantitative Real-time Reverse
Transcription (RT-qPCR)
Mice were anesthetized and perfused intracardially with PBS
before organs harvest. RNA was isolated from organs, reverse-
transcribed and subjected to quantitative RT-PCR (RT-qPCR) as
Figure 3. Hepatocytes respond to IFN-a but not to IFN-l. A: Fluorescence microscopy images showing the IFN response (Mx1, green) in
hepatocytes (HNF4, red), in liver sections from Mx-IFNLR10/0 and Mx-IFNAR10/0 mice infected for 48 hours with influenza A virus strain TURH. Scale
bar: 15 mm. B: Fluorescence microscopy images showing the IFN-l response (Mx1, green) in cholangiocytes (cytokeratin, red) in liver sections from
Mx-IFNAR10/0 mice, mock-infected or infected for 48 hours with the TURH strain of influenza A virus or mock-infected. Scale bar: 15 mm. Results are
representative of two independent experiments.
doi:10.1371/journal.pone.0087906.g003
Lack of IFN-l Response in Mouse Hepatocytes
PLOS ONE | www.plosone.org 5 January 2014 | Volume 9 | Issue 1 | e87906
previously described [22], using SybrGreen and the MyIQTM
apparatus (Biorad). The primer sequences used are described in
Table 1. Standards consisted of 10-fold dilutions of known
concentrations of a plasmid carrying a PCR fragment from cDNA
encoding the influenza A virus matrix protein M1, OASl2, OAS1,
MxA or b-actin. All RT-qPCR results were normalized to b-actin
cDNA levels in a sample.
Immunohistofluorescence
Mx-wt mice or chimeric human liver-uPA-SCID mice were
anesthetized and perfused intracardially with PBS containing 1–
Figure 4. Human hepatocytes in a mouse model respond to IFN-l. A: RT-qPCR analysis of mouse Oasl2 (mOasl2) expression in the livers and
kidneys of Alb-uPA-SCID transgenic mice electroinjected with IFN-a or IFN-l expression plasmids or with the empty plasmid (mock). Results are
expressed as mOasl2 cDNA copies per 103 copies of b-actin cDNA B: RT-qPCR analysis of human MxA (hMxA) and OAS1 (hOAS1) expression in the
livers of Alb-uPA-SCID transgenic mice electroinjected with IFN-a or IFN-l expression plasmids or with the empty plasmid (mock). Results are
expressed as hMxA or hOAS1 cDNA copies per 103 copies of b-actin cDNA. *p#0.05. C: Fluorescence microscopy images showing co-
immunostainings of human MxA and human cytokeratin 18 in liver sections of Alb-uPA-SCID transgenic mice electroinjected with IFN-a or IFN-l
expression plasmids or with the empty plasmid (mock). Hoechst: nuclear staining. Results are representative of two independent experiments.
doi:10.1371/journal.pone.0087906.g004
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4% of paraformaldehyde (PFA) before organ harvest. Freshly
collected organs were immersed in 4% buffered formaldehyde for
4 h at room temperature and then paraffin-embedded. Tissues
were cut at 4 mm with a microtome and sections were placed on
SuperFrost Plus slides, dried at 37uC overnight, and processed by
standard methods for immunohistochemistry. Briefly, tissue
sections were deparaffinized, permeabilized for 5 min in PBS/
0.1% Triton X-100 and washed in PBS. Unmasking of antigens
was done by treating tissue sections for 60 min at 97uC in 10 mM
sodium citrate buffer (pH 5.8) before blocking with Antibody
Diluent with Background Reducing Components (Dako #S3022).
Primary and secondary antibodies were diluted in blocking
solution.
The following primary antibodies and dilutions were used:
rabbit polyclonal anti-influenza virus (FLUAV #178, Freiburg
University) at 1:1000, rabbit polyclonal anti-mouse Mx1 at 1/200
(AP5#2771, [23]), mouse monoclonal anti-human HNF4a/
NR2A1 (HNF4) at 1/300 (R&D Systems #PP-H1415-00), mouse
monoclonal anti-pan cytokeratin at 1/500 (Sigma, #C5992),
mouse monoclonal anti-human MxA at 1/2500 (#M143 [24]),
rabbit polyclonal anti-human MxA at 1/2500 (#41, Freiburg
University), mouse monoclonal anti-human cytokeratin 18 (Clone
DC 10, Dako, # M 7010), rabbit polyclonal anti-human albumin
(Merck Millipore, #126584).
Secondary antibodies were AlexaFluor conjugates (Invitrogen).
The following antibodies and dilutions were used: goat anti-mouse
AlexaFluor 594 cross-adsorbed at 1/400 (HNF4 and Cytokeratin
immunostainings), goat anti-rabbit AlexaFluor 594 at 1/400
(albumin immunostainings), goat anti-rabbit HRP at 1/100
(influenza virus, Mx1 and MxA (#41) immunostainings) and goat
anti-mouse HRP at 1/100 (MxA (#143) immunostainings). For
influenza A virus, Mx1 and MxA immunostainings, detection
required amplification using tyramide signal amplification (TSA)
(#NEL701001KT and NEL702001KT, PerkinElmer). Nuclei
were stained with Hoechst33258 (Roche) or DAPI (Vectashield
H-1200, Vector Laboratories).
Statistical Analysis
Data were analyzed with Prism version 4.0c using one-tailed
Mann-Whitney U test. P values #0.05 were considered significant.
Results
Cholangiocytes but not Hepatocytes Respond to IFN-l in
Mouse Livers
Previously published data from in vivo experiments show a very
weak IFN-l response in the mouse liver [8,13]. As a first approach
to identify IFN-l-responsive cells in mouse liver, we performed
Mx1 immunolabelings on liver sections from mice that were
electroinjected with IFN expression vectors. We used the
previously described mice that carry a functional Mx1 gene so
that the IFN response can be detected by immunohistofluores-
cence using antibodies detecting Mx1, which gives a characteristic
nuclear signal. Mx-IFNLR10/0, Mx-IFNAR10/0 or Mx-IFNAR10/
0 IFNLR10/0 mice were electroinjected in the tibialis anterior
muscle with IFN-l3 or IFN-a6T expression vectors, or with the
empty vector (pcDNA3). This method allows a long lasting
expression of circulating IFN [8]. Mx1 immunodetection was used
to identify IFN-responding cells. IFN-l-responding cells were
identified in Mx-IFNAR10/0 mice electroinjected with the IFN-l-
expressing plasmid, whereas IFN-a-responding cells were identi-
fied in Mx-IFNLR10/0 mice electroinjected with the IFN-a-
expressing plasmid. Mx-IFNAR10/0 IFNLR10/0 mice served as
negative controls. We observed a response to IFN-l in cytokeratin-
positive cholangiocytes, but not in hepatocytes (Fig. 1A). The
response to IFN-a differed strikingly from the response to IFN-l.
Many interstitial cells as well as endothelial cells responded to IFN-
a. Surprisingly, however, no IFN-a response was observed in
hepatocytes (Fig. 1B). As expected, the liver of Mx-IFNAR10/0
IFNLR10/0 mice responded neither to IFN-a nor to IFN-l,
although very few unidentified interstitial cells appeared to
constitutively express Mx1 (data not shown).
It was reported that prolonged stimulation of liver cells with
IFN-a triggers desensitization of the IFN response pathway [25].
Such refractoriness was not observed, however, in the case of IFN-
l [26]. To rule out that the lack of Mx1 expression in mouse
hepatocytes was related to IFN refractoriness, we monitored Mx1
expression in the liver of mice subcutaneously injected with a
single dose of recombinant IFN-a or IFN-l (Fig. 1C). In this case,
Mx1 expression could be readily detected in hepatocytes of Mx-
IFNLR10/0 mice treated with IFN-a. However, as in the previous
experiment, no Mx1 expression was detected in hepatocytes of
Mx-IFNAR10/0 mice treated with IFN-l.
Hepatocytes do not Respond to IFN-l in Livers Infected
with a Hepatotropic Strain of Influenza A Virus
The apparent absence of IFN response in hepatocytes observed
in the previous experiment was unexpected. It might be explained
by low-level supply of IFN from the bloodstream after plasmid
electroinjection-based expression in mice. This artificial system
might not mimic the local high concentrations of IFN which are
probably reached in virus-infected tissues. To test whether
hepatocytes can respond to high local concentrations of IFN,
Mx-IFNLR10/0 and Mx-IFNAR10/0 mice were infected for 24
(not shown) and 48 hours, respectively, with mouse hepatotropic
influenza A virus strain TURH. RT-qPCR and immunohisto-
chemistry confirmed the infection of livers and lungs (Fig. 2A–C).
Livers and lungs of Mx-IFNAR10/0 mice were much more
strongly infected than those of Mx-IFNLR10/0 mice, in agreement
with the previous report showing stronger influence of type-I IFN
on influenza A virus infection [13]. Both in the liver and in the
lung, Oasl2 mRNA expression was strongly induced in IFNAR10/0
mice (Fig. 2D–E), suggesting that these tissues readily responded to
IFN-l produced in response to infection. IFN was produced
locally in response to viral infection, as transcription of both IFN-b
and IFN-l genes was strongly upregulated in the livers of infected
Mx-IFNAR10/0 mice (Fig. 2F–G).
To study the IFN response in hepatocytes, we performed Mx1
immunolabelings on liver sections from mice infected for 48 hours
(Fig. 3). In infected Mx-IFNLR10/0 mice, many scattered Mx1-
positive hepatocytes were detected in the liver (Fig. 3A), with the
response being most intense close to infection foci, confirming the
ability of hepatocytes to respond to type I IFN. In contrast, no
response to type III IFN was detected in hepatocytes of Mx-
IFNAR10/0 mice. In livers of these mice, the only cells responding
to type III IFN were the cholangiocytes, as previously observed
with electroinjected animals (Fig. 3B). Thus, in spite of massive
local IFN production, hepatocytes did not respond to type III IFN,
while they responded to type I IFN.
Human but not Mouse Hepatocytes Respond to IFN-l
The data presented above, as well as previously published works
show that, unlike human hepatocytes [9,11], mouse hepatocytes
do not respond to IFN-l [8,13]. This raised the question of
whether the lack of responsiveness of mouse hepatocytes to IFN-l
was due to the nature of the hepatocytes, or to the micro-
environment in mouse livers. To answer this question we used Alb-
uPA-SCID transgenic mice, which were engrafted with human
Lack of IFN-l Response in Mouse Hepatocytes
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hepatocytes. These mice have chimeric livers containing both
mouse and human hepatocytes [18,27,28].
Chimeric mice were electroinjected either with a plasmid
expressing human IFN-l3, or a mix of plasmids expressing human
and mouse IFN-a, or with the empty vector (pcDNA3). The
antiviral activity of type I IFN is species-specific [29,30].
Therefore, in order to monitor the IFN-a response in chimeric
livers, a 50:50 mixture of plasmids expressing human IFNa2 and
mouse IFN-aA was used for electroinjection. In contrast, mouse
cells can respond to human IFN-l and vice versa (Fig. S1).
Therefore, we used a single plasmid expressing hIFN-l3 for
electroinjection. At 7 days post-electrotransfer, ISG expression
was measured in the kidneys and livers, using RT-qPCR, to
evaluate the overall IFN response (Fig. 4A–B). The response of
mouse cells was quantified by measuring expression of mouse
Oasl2. The response of human hepatocytes was quantified by
measuring expression of human OAS1 and MXA. In IFN-a-
expressing mice, we observed a significant increase of mouse Oasl2
transcripts in chimeric livers (p = 0.05). As in previous experi-
ments, no significant mouse Oasl2 response to IFN-l was detected
in livers (p = 0.2), while a clear response to this cytokine was
observed in kidneys (p = 0.05) (Fig. 4A). Importantly, we observed
very good human OAS1 and MXA responses to IFN-l in chimeric
livers (p = 0.05) (Fig. 4B).
The prominent IFN-l response of human hepatocytes was
further visualized by immunohistofluorescence analysis of liver
sections. Human hepatocytes were identified using anti-human
cytokeratin 18 (Fig. 4C) or anti-human albumin antibodies (Fig.
S2). In chimeric mice treated with either IFN-l or IFN-a, most
human hepatocytes were strongly positive for MxA. Taken
together, these results show that human hepatocytes in a mouse
environment are able to respond to type III IFN.
Discussion
In this work, we highlight the lack of responsiveness of mouse
hepatocytes to IFN-l in vivo. Even when high amounts of IFN-l
were produced locally after influenza A virus infection, the IFN-l
response was confined to cholangiocytes. Previous works showed
that mouse livers responded poorly to IFN-l [8,13]. However,
using RT-qPCR and Northern blot analysis a recent study showed
that primary mouse hepatocytes can respond to IFN-l [9].
Nonetheless, since these results were obtained in vitro, it remains
possible that the hepatocytes did not behave exactly as they would
in vivo. Here, we analyzed the IFN-l response, at the cellular level,
in the intact mouse liver. We show that cholangiocytes were the
predominant cells responding to IFN-l in mouse liver. No
response to IFN-l was observed in hepatocytes, even in infected
livers where high amounts of IFN were expected to be produced
locally.
Human hepatocytes, however, were shown to be responsive to
IFN-l in vitro [9,11]. In vivo, good antiviral activity was observed
against HCV with PEG-IFN-l [12]. Clinical studies are currently
ongoing for the use of IFN-l in the treatment of viral diseases in
human.
However, to our knowledge, a formal proof that hepatocytes
directly respond to IFN-l is still lacking. The most compelling
evidences that IFN-l acts on human hepatocytes are the detection
of IFNLR1 by immunohistochemistry on hepatocytes in sections
of hepatic biopsies [11], and the relatively high expression level of
IFNLR1 mRNA in human hepatocytes engrafted in mice with
chimeric livers [31].
Using Alb-uPA-SCID mice with chimeric livers we demon-
strated that human hepatocytes present in a mouse environment
can respond to circulating IFN-l. This result does not unequiv-
ocally prove that human hepatocytes are physiologically respon-
sive to IFN-l. Indeed, although these hepatocytes were not
cultured in vitro, one cannot completely rule out the fact that
IFNLR1 expression was consequent to the hepatocyte isolation
procedure. Yet, it is very likely that human hepatocytes do respond
to IFN-l and we postulate that epigenetic factors might silence
IFN-l receptor expression in mouse but not human hepatocytes.
Our results further show that the lack of responsiveness of
mouse hepatocytes to IFN-l is not due to the murine environment
since human hepatocytes present in the same tissue readily
responded to IFN-l.
In conclusion, our data suggest that human but not mouse
hepatocytes are responsive to IFN-l. This highlights the existence
of some limits to the use of mouse models in the study of human
hepatotropic pathogens.
Supporting Information
Figure S1 Human-mouse cross-reactivity of IFN-l. A–B.
RT-qPCR analysis of muOASl2 in LKR-10 cells (A) and huMxA
in HeLa cells (B) treated with human or mouse IFN-a and IFN-l.
Means and SD of 4 samples. *: p#0.05, NS: non significant.
(TIF)
Figure S2 Human hepatocytes in a mouse model
respond to IFN-l. Fluorescence microscopy images showing
co-immunostainings of human MxA and human albumin in liver
sections of Alb-uPA-SCID transgenic mice electroinjected with
IFN-a or IFN-l expression plasmids or with the empty plasmid
(mock). Hoechst: nuclear staining. Results are representative of
two independent experiments.
(TIF)
Materials and Methods S1 This section describes the cells
[33,34] and procedures used to produce and quantify IFNs.
(DOCX)
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